Endocrine Abstracts

Objectives: The development of drugs to aid weight loss as an adjunct to dietary and lifestyle recommendations prior to surgical treatment of obesity may help in the management of these patients. To compare the percentage of weight loss among patients who received dietary recommendations (Group 1) and lifestyle recommendations vs those who added arGLP1 semaglutide 1 mg sc (Group 2) or liraglutide 3 mg sc (Group 3) to these recommendations, analysing other variables such as the presence of diabetes mellitus.

Methods: Patients undergoing bariatric surgery from 01/01/2022 to 01/09/2023 were reviewed using normality, t-Student, ANOVA and non-parametric tests with the Jamovi v2.3.28 software.

Results: Included were 67 females and 31 males with a mean age 49.2 ± 8.97 SD years with a baseline weight 128 ± 20.1 kg, who followed treatment for 29.2 ± months: (1) diet: 48 patients 28.33 ± 22.9 SD months, (2) diet with semaglutide 1 mg sc: 21 patients 22.14 ± 18.23 SD months and (3) diet with liraglutide 3 mg sc: 19 patients 11.42 ± 14.15 SD months. At the end of follow-up they lost: - 5.98% ±7.82 SD kg. In the percentage of weight loss there were no differences between sexes, whether or not they used aGLP1, but the loss was greater in those treated pharmacologically (P<0.001), being -10.2 ± 7.89 SD with diet and drugs and -3.09 ± 6.37 SD Kg with diet alone. 83% achieved losses greater than 5% and 48% greater than 10% with pharmacological treatment. There was no difference when comparing Liraglutide sc vs Semaglutide sc in weight loss. In the 26 DM2 patients treated with arGLP-1, weight loss was lower (-8.8% ± 6.42 kg) than in non-DM2 patients (-10.6% ± 7.29 kg) (P<0.05).

Conclusions: Adding arGLP-1 to dietary and lifestyle changes treatment improves the percentage of weight loss achieved before bariatric surgery, reaching the usual recommended 10% weight loss, being more effective in non-DM, without differences between sexes or arGLP-1 used.